Home›Research›Compare›Angiotensin (1-7) vs SS-31
Peptide ComparisonAngiotensin (1-7) vs SS-31
Both are Longevity & Cellular peptides.
Angiotensin (1-7)
Ang-(1-7)
Half-life: ~9–10 sec (rat)
No providers listed yet
SS-31
Elamipretide
Half-life: ~2-3 hours
51 providers listed
SS-31 is FDA-approved, while Angiotensin (1-7) is investigational — the clearest structural difference between them.
Angiotensin (1-7)
Half-life
~9–10 sec (rat)
SS-31
Half-life
~2-3 hours
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Angiotensin (1-7) |
| Further along in FDA review | SS-31 |
| Less frequent dosing (longer half-life) | Angiotensin (1-7) |
| More provider options (0 vs 51) | SS-31 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Angiotensin (1-7)
SS-31
Angiotensin (1-7)
Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study.
Angiotensin-(1-7) improves oxygenation in mechanically ventilated COVID-19 patients: a randomized phase 1-2 s…
Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…
The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.
+5 more
SS-31
Intrarenal Infusion of Elamipretide (MTP-131) During Stenting in Patients With Atherosclerotic Renovascular D…
Elamipretide (MTP-131) Alters the Landscape of Myocardial Lipids and Reduces Oxidative Stress Following Cardi…
Peroxiredoxin Ⅲ safeguards cardiac function against doxorubicin by regulating mitochondrial quality control v…
Protective Effect of Mitochondria-Targeted Polydopamine Nanoparticles in Alleviating Hepatic Ischemia-Reperfu…
+6 more
About Angiotensin (1-7)
Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.
About SS-31
Targets cardiolipin in inner mitochondrial membrane; stabilizes cristae structure; enhances electron transport chain efficiency; reduces mitochondrial ROS
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Angiotensin (1-7)
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
SS-31
No structured contraindication profile is available for this compound yet. This compound is FDA-approved — consult the official prescribing information or a qualified clinician.
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Angiotensin (1-7)
Not enough vendor pricing yet.
SS-31
Where to source these peptides
Angiotensin (1-7)
Browse directory →
Providers offeringSS-31
51 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Angiotensin (1-7) vs SS-31 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/angiotensin-1-7/ss-31